Poland· PL-100475108

Amvuttra

A vutrisiran product containing vutrisiranum, registered in Poland by Alnylam Netherlands B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC N07XX18

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAmvuttraATCN07XX18REGISTER NO.PL-100475108PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Vutrisiran is registered in 14 of 19 countries.

Countries holding a registration under ATC N07XX18 (vutrisiran), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Vutrisiran · ATC N07XX18

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of vutrisiran costs, country by country.

Normalised to the WHO defined daily dose (0.278 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Vutrisiran · price per daily dose (0.278 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1135.51
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Vutrisiranum
Manufacturer
Alnylam Netherlands B.V.
Country
Poland (PL)
ATC code
N07XX18
ATC class
Vutrisiran
Defined daily dose
0.278 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    04150181110077

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/90bc1a3a-16df-4fae-b4da-8bc2530e85b6
GET /v1/drugs/90bc1a3a-16df-4fae-b4da-8bc2530e85b6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań w ampułko-strzykawce",
  "source": "urpl",
  "strength": "25 mg",
  "packaging": "Rpz ¦ EU/1/22/1681/001 ¦ 147360\n1 amp.-strzyk. 0,5 ml\n¦ UR/Z/4b/102/23 - 04150181110077 ¦ UR/Z/4b/083/25 - 04150181110077 ¦ UR/Z/4b/005/26 - 04150181110077 ¦ UR/Z/4b/259/26 - 04150181110077",
  "substance": "Vutrisiranum 25 mg",
  "common_name": "Vutrisiranum",
  "pl_product_id": "100475108",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about vutrisiran.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.